These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
674 related articles for article (PubMed ID: 28869439)
1. Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the clinical stages and cancer metastasis in hepatocellular carcinoma patients. Chen J; Cao SW; Cai Z; Zheng L; Wang Q Cancer Biomark; 2017 Dec; 20(4):487-498. PubMed ID: 28869439 [TBL] [Abstract][Full Text] [Related]
2. An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients. Liu YK; Hu BS; Li ZL; He X; Li Y; Lu LG Hepatol Int; 2016 Jul; 10(4):640-6. PubMed ID: 27115761 [TBL] [Abstract][Full Text] [Related]
3. Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease. Li YM; Xu SC; Li J; Han KQ; Pi HF; Zheng L; Zuo GH; Huang XB; Li HY; Zhao HZ; Yu ZP; Zhou Z; Liang P Cell Death Dis; 2013 Oct; 4(10):e831. PubMed ID: 24091674 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic Value of Different Phenotype Circulating Tumor Cells in Hepatocellular Carcinoma. Cheng Y; Luo L; Zhang J; Zhou M; Tang Y; He G; Lu Y; Wang Z; Pan M J Gastrointest Surg; 2019 Dec; 23(12):2354-2361. PubMed ID: 30805878 [TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma. Sun YF; Guo W; Xu Y; Shi YH; Gong ZJ; Ji Y; Du M; Zhang X; Hu B; Huang A; Chen GG; Lai PBS; Cao Y; Qiu SJ; Zhou J; Yang XR; Fan J Clin Cancer Res; 2018 Feb; 24(3):547-559. PubMed ID: 29070526 [No Abstract] [Full Text] [Related]
6. Epithelial-mesenchymal transition and GALC expression of circulating tumor cells indicate metastasis and poor prognosis in non-small cell lung cancer. Liu DG; Xue L; Li J; Yang Q; Peng JZ Cancer Biomark; 2018; 22(3):417-426. PubMed ID: 29758927 [TBL] [Abstract][Full Text] [Related]
7. Classification of circulating tumor cells by epithelial-mesenchymal transition markers. Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322 [TBL] [Abstract][Full Text] [Related]
8. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer. Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810 [TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor Cell Phenotype Indicates Poor Survival and Recurrence After Surgery for Hepatocellular Carcinoma. Ou H; Huang Y; Xiang L; Chen Z; Fang Y; Lin Y; Cui Z; Yu S; Li X; Yang D Dig Dis Sci; 2018 Sep; 63(9):2373-2380. PubMed ID: 29926241 [TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma. Qi LN; Xiang BD; Wu FX; Ye JZ; Zhong JH; Wang YY; Chen YY; Chen ZS; Ma L; Chen J; Gong WF; Han ZG; Lu Y; Shang JJ; Li LQ Cancer Res; 2018 Aug; 78(16):4731-4744. PubMed ID: 29915159 [TBL] [Abstract][Full Text] [Related]
11. Twist Expression in Circulating Hepatocellular Carcinoma Cells Predicts Metastasis and Prognoses. Yin LC; Luo ZC; Gao YX; Li Y; Peng Q; Gao Y Biomed Res Int; 2018; 2018():3789613. PubMed ID: 30046595 [TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells undergoing EMT are poorly correlated with clinical stages or predictive of recurrence in hepatocellular carcinoma. Chen Y; Li S; Li W; Yang R; Zhang X; Ye Y; Yu J; Ye L; Tang W Sci Rep; 2019 May; 9(1):7084. PubMed ID: 31068623 [TBL] [Abstract][Full Text] [Related]
13. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis. Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050 [TBL] [Abstract][Full Text] [Related]
14. Cell-surface major vault protein promotes cancer progression through harboring mesenchymal and intermediate circulating tumor cells in hepatocellular carcinomas. Lee HM; Joh JW; Seo SR; Kim WT; Kim MK; Choi HS; Kim SY; Jang YJ; Sinn DH; Choi GS; Kim JM; Kwon CHD; Chang HJ; Kim DS; Ryu CJ Sci Rep; 2017 Oct; 7(1):13201. PubMed ID: 29038587 [TBL] [Abstract][Full Text] [Related]
15. Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer. Chen J; Cao S; Situ B; Zhong J; Hu Y; Li S; Huang J; Xu J; Wu S; Lin J; Zhao Q; Cai Z; Zheng L; Wang Q J Exp Clin Cancer Res; 2018 Jun; 37(1):127. PubMed ID: 29954422 [TBL] [Abstract][Full Text] [Related]
16. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells. Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758 [TBL] [Abstract][Full Text] [Related]
17. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer. Zhao R; Cai Z; Li S; Cheng Y; Gao H; Liu F; Wu S; Liu S; Dong Y; Zheng L; Zhang W; Wu X; Yao X Oncotarget; 2017 Feb; 8(6):9293-9302. PubMed ID: 28030836 [TBL] [Abstract][Full Text] [Related]
18. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer. Li S; Chen Q; Li H; Wu Y; Feng J; Yan Y Clin Transl Oncol; 2017 Sep; 19(9):1147-1153. PubMed ID: 28374320 [TBL] [Abstract][Full Text] [Related]
19. Mesenchymal circulating tumor cells and Ki67: their mutual correlation and prognostic implications in hepatocellular carcinoma. Yang X; Ni H; Lu Z; Zhang J; Zhang Q; Ning S; Qi L; Xiang B BMC Cancer; 2023 Jan; 23(1):10. PubMed ID: 36600214 [TBL] [Abstract][Full Text] [Related]
20. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]